Corcept Therapeutics Inc. CORT announced initial efficacy data from its phase I/II trial on Korlym in combination with the chemotherapy drug, Halaven, at the 2015 San Antonio Breast Cancer Symposium.
The combination is being evaluated for the treatment of patients with glucocorticoid receptor (GR)-positive, metastatic, triple-negative breast cancer (TNBC). Corcept is evaluating if the addition of Korlym to Halaven improves the efficacy of the chemotherapy drug in patients whose TNBC tumors express GR.
Initial results from the trial showed that out of the 15 enrolled patients with GR-positive TNBC, only 1 exhibited a partial response (defined as a 30% or greater reduction in tumor size), 7 had stable disease and 5 had progressive disease.
We note that the trial is being conducted in two phases. The first phase determined the maximum-tolerated combined dose of Korlym and eribulin – 300 mg of Korlym daily with 1.1 mg/m2 of eribulin taken on days one and eight of a three-week cycle. This dose is now being administered to patients in the second ongoing efficacy phase, which will enroll 20 patients with GR-positive, metastatic TNBC.
We remind investors that Korlym is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who are suffering from type II diabetes or glucose intolerance and have failed or are not suitable for surgery.
Korlym is Corcept’s lead drug and the company is currently working on developing it for additional indications.
Corcept currently sports a Zacks Rank #1 (Strong Buy). Other top-ranked stocks in the health care sector include Baxalta, Inc. BXLT, Mylan MYL and Pluristem Therapeutics, Inc. PSTI. All three sport the same Zacks Rank as Corcept.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment